Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.04B P/E - EPS this Y 4.10% Ern Qtrly Grth -
Income -227.04M Forward P/E -6.08 EPS next Y 0.90% 50D Avg Chg 3.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 3.00%
Dividend N/A Price/Book 5.51 EPS next 5Y - 52W High Chg -31.00%
Recommedations 1.80 Quick Ratio 9.08 Shares Outstanding 109.45M 52W Low Chg 30.00%
Insider Own 0.13% ROA -37.18% Shares Float 70.23M Beta 0.03
Inst Own 112.37% ROE -62.92% Shares Shorted/Prior 9.73M/10.23M Price 12.52
Gross Margin - Profit Margin - Avg. Volume 692,954 Target Price 16.40
Oper. Margin - Earnings Date Oct 31 Volume 817,742 Change -6.15%
About Cogent Biosciences, Inc.

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Cogent Biosciences, Inc. News
11/05/24 Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) Meeting
10/23/24 Cogent Biosciences Announces Pipeline Expansion into KRAS and Poster Presentations at the 2024 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics
10/20/24 Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation
10/09/24 Analysts Rate Cogent Biosciences, Inc. (COGT) as Moderate Buy with $15 Target
09/03/24 Cogent Biosciences Announces Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST) Has Completed Enrollment and Advanced Past Interim Futility Analysis
08/06/24 Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial Results
06/27/24 Cogent Biosciences Announces Positive FDA Meeting and Alignment on MS2D2, a Novel Patient Reported Outcome Measure for the SUMMIT trial
06/14/24 Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
05/23/24 Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer
05/23/24 Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting
05/13/24 We Think Cogent Biosciences (NASDAQ:COGT) Can Afford To Drive Business Growth
05/07/24 Cogent Biosciences Reports First Quarter 2024 Financial Results
04/09/24 Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor
02/28/24 COGT Reports Full Year 2023 Financial Results and Business Highlights
02/26/24 Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
02/22/24 Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
02/14/24 Cogent Biosciences Announces Oversubscribed $225 Million Private Placement
02/05/24 Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting
01/09/24 Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics
01/02/24 Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
COGT Chatroom

User Image NVDAMillionaire Posted - 2 days ago

$COGT Cogent Biosciences (COGT): A Trailblazer in Genetically-Driven Disease Therapies https://beyondspx.com/article/cogent-biosciences-inc-cogt-a-promising-precision-therapeutics-company-poised-for-growth

User Image IN0V8 Posted - 1 week ago

$COGT Opportunity JP Morgan raises target price to $21 from $19

User Image Stockguru101 Posted - 1 week ago

$COGT how we holding up bulls?! 2025 is going to be a huge year for this company. * Key Point for me tho is if trial for Osteoporosis is a success & they start mass producing pills to patients who need it. We see a $75. It’s such a rare disease with no medications out there and heard is very painful and makes you weak everyday.. it just seems that it was originally such a rare disease that no one truly tried to developed a medicine for it but as more and more people developed it, companies began working. COGT at the forefront. Please stay strong and hold and buy bulls!

User Image srwit Posted - 1 week ago

$COGT ..PSTX

User Image Bromberger Posted - 2 weeks ago

$COGT https://www.tipranks.com/news/the-fly/cogent-biosciences-down-after-bezuclastinib-abstract-released

User Image justiceforb_85 Posted - 2 weeks ago

$COGT why the drop??

User Image _www_larval_com_ Posted - 2 weeks ago

$COGT just reverted 4% higher to -14% (~1Mv) moments ago, 11/15 options, follow for more volatility.

User Image Thestocktraderhubzee Posted - 10/24/24

WATCHLIST OCT 24 2024 $COGT Needham Reiterates Buy on Cogent Biosciences, Maintains $16 Price Target $DBVT HC Wainwright & Co. Maintains Buy on DBV Technologies, Raises Price Target to $7 $ENPH RBC Capital Maintains Sector Perform on Enphase Energy, Lowers Price Target to $85 $CADE RBC Capital Maintains Sector Perform on Cadence Bank, Raises Price Target to $36 $WBA Jefferies Maintains Hold on Walgreens Boots Alliance, Lowers Price Target to $9

User Image briefingcom Posted - 10/23/24

$COGT: Cogent Biosciences announces the addition of a potent and selective KRAS inhibitor to its pipeline https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20241023070645COGT&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

User Image Doozio Posted - 10/22/24

$COGT 🧠⏰♾️

User Image Doozio Posted - 1 month ago

$COGT they are only slow n steady in da FUTUre of 🧠⏰ until they aren’t during 🧠⏰♾️

User Image justiceforb_85 Posted - 1 month ago

$COGT slow but steady rise. Have faith in bezuclastinib.

User Image Stockguru101 Posted - 1 month ago

$COGT I’m in.

User Image TAFox Posted - 09/26/24

$COGT what happened after hours?

User Image Thestocktraderhubzee Posted - 09/25/24

WATCHLIST SEP 25 2024.. $AX Wedbush Maintains Neutral on Axos Financial, Lowers Price Target to $75 $AHR B of A Securities Maintains Buy on American Healthcares, Raises Price Target to $31 $APLS Wells Fargo Maintains Equal-Weight on Apellis Pharmaceuticals, Lowers Price Target to $43 $COGT Citigroup Maintains Buy on Cogent Biosciences, Raises Price Target to $15 $EL DA Davidson Maintains Buy on Estee Lauder Cos, Maintains $130 Price Target

User Image cob7178 Posted - 2 months ago

$COGT Sorry, but i bought some shares ensuring this stock will go down

User Image kolococo Posted - 2 months ago

$COGT adding

User Image PenkeTrading Posted - 2 months ago

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Cogent Biosciences Inc. Is that bullish or bearish? $COGT #COGT #nasdaq #tradingsignals #technicalanalysis

User Image Thestocktraderhubzee Posted - 2 months ago

$COGT Baird Maintains Neutral on Cogent Biosciences, Raises Price Target to $10

User Image Doozio Posted - 2 months ago

$COGT 🧠⏰♾️

User Image Stock_Titan Posted - 2 months ago

$COGT Cogent Biosciences Announces Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST) Has Completed Enrollment and Advanced Past Interim Futility Analysis https://www.stocktitan.net/news/COGT/cogent-biosciences-announces-phase-3-peak-trial-in-patients-with-ilx2ofna2ww1.html

User Image Doozio Posted - 3 months ago

$COGT 🧠⏰ wen?

User Image epsguid Posted - 3 months ago

$COGT reported a loss of $0.59, consensus was ($0.55) via @eWhispers #epsmiss http://eps.sh/d/cogt

User Image Stock_Titan Posted - 3 months ago

$COGT Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial Results https://www.stocktitan.net/news/COGT/cogent-biosciences-reports-recent-business-highlights-and-second-zua5xasl59d8.html

User Image NVDAMillionaire Posted - 07/31/24

$COGT Cogent Biosciences, Inc. (COGT): A Promising Precision Therapeutics Company Poised for Growth http://beyondspx.com/2024/07/30/cogent-biosciences-inc-cogt-a-promising-precision-therapeutics-company-poised-for-growth/

User Image StockConsultant Posted - 07/29/24

$COGT Cogent Biosciences stock watch for a narrow range breakout above 9.64, target 11 area at https://stockconsultant.com/?COGT

User Image srwit Posted - 4 months ago

$COGT guessing small caps will run with possible interest rate cut in september and don't bet against steve cohen..phase 3 on de ck

User Image Doozio Posted - 4 months ago

$COGT a 🧠👀 is NOW chop chop huckleberries 🧠⏰

User Image Bromberger Posted - 4 months ago

$COGT this stock is completly crazy. One day +10% another -10% 😵‍💫 But I think it goes in the good direction 🔝

User Image TickerDD_com Posted - 4 months ago

From 6/18/2024, looking back across 21 Month-Ends for COGT, Percentage Change of Average Monthly Price had More Negatives (64%) while Percentage Change of Average Monthly Volume had All Positives (100%) $COGT #COGT #COGTStock #TickerDD #COGTPrice https://www.youtube.com/watch?v=mg47yjNgT74

Analyst Ratings
Citigroup Buy Sep 24, 24
Baird Neutral Sep 5, 24
HC Wainwright & Co. Buy Sep 3, 24
JP Morgan Overweight Aug 7, 24
Needham Buy Aug 7, 24
Needham Buy Jun 27, 24
HC Wainwright & Co. Buy Jun 17, 24
Needham Buy Jun 17, 24
Wedbush Neutral May 24, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Fairmount Funds Management LLC - - Jun 16 Buy 8.25 1,200,000 9,900,000 2,472,124 06/21/22